Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

Sadler HA, Stenglein MD, Harris RS, Mansky LM.

J Virol. 2010 Jul;84(14):7396-404. doi: 10.1128/JVI.00056-10. Epub 2010 May 12.

2.

[Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].

Fan B, Cen S, Jiang JD.

Yao Xue Xue Bao. 2008 Jul;43(7):678-82. Review. Chinese.

PMID:
18819469
3.

[Research methods of anti-HIV-1 inhibitors targeting at Vif-APOBEC3G axis].

Qiao X, Zhang W, Li Z, Zeng Y.

Zhongguo Zhong Yao Za Zhi. 2011 Mar;36(6):806-9. Review. Chinese.

PMID:
21710755
4.

[Progress in the study of HIV-1 Vif and related inhibitors].

Li ZY, Zhan P, Liu XY.

Yao Xue Xue Bao. 2010 Jun;45(6):684-93. Review. Chinese.

PMID:
20939174
5.

[Recent advances in the study of mechanism of APOBEC3G against virus].

Zhu YP, Jiang JD, Peng ZG.

Yao Xue Xue Bao. 2014 Jan;49(1):30-6. Review. Chinese.

PMID:
24783502
6.

APOBEC proteins and intrinsic resistance to HIV-1 infection.

Malim MH.

Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):675-87. doi: 10.1098/rstb.2008.0185. Review.

7.

Vif and Apobec3G in the innate immune response to HIV: a tale of two proteins.

Farrow MA, Sheehy AM.

Future Microbiol. 2008 Apr;3(2):145-54. doi: 10.2217/17460913.3.2.145. Review.

PMID:
18366335
8.

HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.

Kremer M, Schnierle BS.

Curr HIV Res. 2005 Oct;3(4):339-44. Review.

PMID:
16250885
9.

HIV-1 Vif, APOBEC, and intrinsic immunity.

Goila-Gaur R, Strebel K.

Retrovirology. 2008 Jun 24;5:51. doi: 10.1186/1742-4690-5-51. Review.

10.

Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif.

Romani B, Engelbrecht S, Glashoff RH.

Arch Virol. 2009;154(10):1579-88. doi: 10.1007/s00705-009-0481-y. Epub 2009 Aug 12. Review.

PMID:
19669862
11.

Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein.

Münk C, Jensen BE, Zielonka J, Häussinger D, Kamp C.

Viruses. 2012 Nov 14;4(11):3132-61. doi: 10.3390/v4113132. Review.

12.

New insights into the role of Vif in HIV-1 replication.

Schröfelbauer B, Yu Q, Landau NR.

AIDS Rev. 2004 Jan-Mar;6(1):34-9. Review.

PMID:
15168739
13.

Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.

Albin JS, Harris RS.

Expert Rev Mol Med. 2010 Jan 22;12:e4. doi: 10.1017/S1462399409001343. Review.

14.

Global HIV-1 molecular epidemiology with special reference to genetic analysis of HIV-1 subtypes circulating in North India: functional and pathogenic implications of genetic variation.

Neogi U, Sood V, Banerjee S, Ghosh N, Verma S, Samrat S, Sharma Y, Saxena A, Husain S, Ramachandran VG, Das S, Sreedhar KV, Goel N, Wanchu A, Banerjea AC.

Indian J Exp Biol. 2009 Jun;47(6):424-31. Review.

PMID:
19634706
15.

[Cellular restriction factors that inhibit human immunodeficiency virus replication: new strategies in antiretroviral therapy].

Moreno-Valencia Y, Alvarez-García LX, Vázquez-Pérez JA.

Rev Invest Clin. 2014 Jul-Aug;66(4):359-68. Review. Spanish.

PMID:
25695302
16.

Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.

Levin JG, Mitra M, Mascarenhas A, Musier-Forsyth K.

RNA Biol. 2010 Nov-Dec;7(6):754-74. Epub 2010 Nov 1. Review.

17.

The origin of genetic diversity in HIV-1.

Smyth RP, Davenport MP, Mak J.

Virus Res. 2012 Nov;169(2):415-29. doi: 10.1016/j.virusres.2012.06.015. Epub 2012 Jun 21. Review.

PMID:
22728444

Supplemental Content

Support Center